Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomivosertib in advanced CRPC
NCT03690141Phase 2Terminated
- Sponsor
- eFFECTOR Therapeutics
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomivosertib in castration-resistant prostate cancer (CRPC), sponsored by eFFECTOR Therapeutics. Primary endpoint: Anti-tumor Response at 52 weeks. Started Nov 2018; status: terminated.
02
Drugs
tomivosertib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03690141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690141.